Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Two Oral Formulations of Elinzanetant in Healthy Women
NCT04845841Phase 1Completed
- Sponsor
- Bayer
- Start
- Apr 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of elinzanetant in vasomotor symptoms and menopause (2 arms), sponsored by Bayer. Primary endpoints: Area Under the Curve of Elinzanetant at Day 15 and Maximum Observed Plasma Concentration of Elinzanetant at Day 15. Started Apr 2021; status: completed.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptomsmenopause
Beyond the preview
Go deeper on NCT04845841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04845841.